Cell Genesys, Inc. (Nasdaq: CEGE) 22% HIGHER; related to FDA panel backing of Dendreon’s (Nasdaq: DNDN) Provenge for prostate cancer. CEGE also has a cancer immunotherapy for prostate cancer.
Spectrum Control Inc. (Nasdaq: SPEC) 12% HIGHER; For the first quarter of fiscal 2007, the Company generated net income of $2,119,000 or 16 cents per share on sales of $32,887,000, compared to net income of $290,000 or two cents per share on sales of $25,560,000 for the first quarter of fiscal 2006.
Antigenics Inc. (Nasdaq: AGEN) 9% HIGHER; FDA panel backing of Dendreon’s (Nasdaq: DNDN) Provenge.
Red Hat (NYSE: RHT)5% HIGHER; reports Q4 earnings of $0.15 per share, ex-items, versus theconsensus of $0.15. Revenues came in at $111.1 million versus theconsensus of $112.6 million. Sees Q1 EPS of $0.15, versus the consensusof $0.15. Sees FY EPS of $0.67-$0.72, versus the consensus of $0.68.Sees FY revs of $510-$520 million versus the consensus of $516.12million.
PMC-Sierra, Inc. (NASDAQ: PMCS)4% HIGHER; announced that it is undertaking a corporate restructuringthat the Company expects will reduce on-going annualized operatingexpenses by an estimated $20 to $24 million per year. Cutting 175 jobs.
TIBCO Software (Nasdaq: TIBX) 4% LOWER; reports Q1 EPS of $0.07, in-line with estimates.(0.07) Revenues were $125.7 million vs. $128.22 million consensus.
Cognos (Nasdaq: COGN)3.4% LOWER; reports Q4 GAAP EPS of $0.67 (non-GAAP EPS was $0.74) vs.consensus of $0.65. Revenues were $284.5 million vs. $278 millionconsensus. Sees Q1 revenues between $230-240 million and Q1 GAAP EPSbetween $0.19 to $0.24 (non-GAAP EPS between $0.28 to $0.33) vs.consensus of $239.54 million and EPS consensus is $0.37. Sees FY08revenues between $1.055-1.075 billion and FY GAAP EPS between $1.66 to$1.73 (non-GAAP EPS between $1.98 to $2.05 vs. consensus of $1.07billion and EPS consensus is $2.03.
Dendreon’s (Nasdaq: DNDN) INDICATED HIGHER
Top Gaining Stocks
Top Losing Stocks